Biocortech and the FondaMental foundation : strategic alliance

April 5th 2011 - Paris, France and Créteil, France - Biocortech, the biotech company dedicated to the development of biological diagnostics for personalized psychiatry, and FondaMental, the foundation of scientific cooperation for mental health research and care, announce the signing of a strategic alliance to validate biomarkers for personalized psychiatry.

This strategic alliance aims at speeding up the availability of qualified blood tests for diagnosis, prognosis, drug selection and monitoring for a personalized medical management of patients suffering from mental health disorders. Concretely, Biocortech and FondaMental will collaborate in clinically validating blood tests measuring biomarkers identified by Biocortech or in FondaMental's network of scientific excellence. Biocortech and FondaMental will define relevant clinical settings and clinical issues to be addressed, build up adequate resources to access blood samples of patients with proper medical records, set up and monitor clinical trials. Biocortech will have responsibility for industrializing and commercializing qualified tests... Biocortech 's Press Release -

Biocortech Issued Key US Patent for a Small-Molecule Antidepressant

Paris, March 10, 2008 - Biocortech announced today that the U.S. Patent and Trademark Office has approved the issuance of a patent for a family of compounds, including BC-22, under development for the treatment of depression. The patent (Application No 11/581,950) was filed on Oct 13, 2006, and is titled, "Derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, and applications thereof".

Clinical depression affects more than 20 million American adults each year. Although available antidepressant medications are effective for a large segment of the population with depression, symptoms may continue despite multiple treatment strategies in 10 to 30 percent of those patients. In addition, current treatment strategies also face other issues, such as delayed onset, dose-limiting side effects, and tolerance/dependence. Thus, there is a clear need for novel depression treatments...
...About Biocortech
Biocortech is a biopharmaceutical company committed to the discovery and development of novel biomarkers and treatments for psychiatric disorders. Biocortech has proprietary assays and technologies to identify biomarkers and develop compounds that can safely and effectively identify and treat diseases such as depression, bipolar disorders, schizophrenia and cognitive deficits. Biocortech has a strong clinical advisory group and drug development capabilities, enabling us to move diagnostic platforms and drugs into humans quickly and efficiently. Biocortech is based in Paris, France... Biocortech's Press Release -